The company is advancing TG4050 in head and neck cancer and possibly to other tumor types based on encouraging Phase I data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results